Insider Buying Heats Up: 3 Small-Cap Stocks with Strong Signals
When insiders buy, investors should pay attention.
Corporate insiders — CEOs, CFOs, board members, and other executives — often have intimate knowledge of their company’s performance and outlook. While they can’t legally trade on material nonpublic information, their decisions to buy shares with their own money are often telling. After all, insiders are just like other investors: they buy when they believe their stock is undervalued and poised to rise.
Academic research supports this. Studies have found that clusters of insider buying — especially when multiple executives purchase shares around the same time — can be a strong bullish signal. According to data from the University of Michigan and Harvard, stocks with heavy insider accumulation tend to outperform the broader market over the following 6 to 12 months.
Recently, several small- and mid-cap companies have seen a notable uptick in insider purchases. In fact, at Eastman Chemical alone, 11 insiders scooped up nearly $2 million worth of stock. That kind of activity is hard to ignore.
Here are three names investors may want to put on their radar.
Company: Eastman Chemical Company (SYM: EMN)
When you see double-digit insiders stepping in to buy shares, it’s a strong vote of confidence. At Eastman Chemical, 11 executives and board members purchased a combined $1.9 million worth of stock, signaling they believe the stock is undervalued at current levels. Eastman Chemical is a specialty materials company with operations in the U.S., China, and globally. Its products span a wide range of industries:
Why does this matter for investors? Specialty chemicals may not be flashy, but they are critical for sectors like agriculture, construction, automotive, and aerospace. Eastman’s broad product lineup provides diversified revenue streams and exposure to global industrial demand. Shares have come under pressure in recent months, creating what insiders clearly see as an opportunity. The fact that so many executives are buying together — rather than just one or two — strengthens the bullish case. |
Paradigm Press
Buffett, Gates and Bezos Quietly Dumping Stocks
The world's wealthiest individuals are making oddly similar moves with their money.
Over the past six months, we've observed a disturbing pattern:
Warren Buffett has liquidated millions of bank stocks.
Bill Gates has sold off 500,000 shares of Microsoft.
And Jeff Bezos is planning to sell Amazon shares worth $4.8 billion.
What is going on?
Former White House advisor Jim Rickards believes they are preparing for a seismic shift in the markets triggered by President Trump's most ambitious economic initiative yet.
In fact, these billionaires aren't just selling – they appear to be moving their wealth into a sector that's likely to soar in the weeks ahead.
Rickards recently revealed exactly which corner of the market these insiders are targeting and how everyday Americans can follow their lead before it's too late.
For full access to this critical briefing, click here immediately.
Company: Kemper Corporation (SYM: KMPR)
Insurance stocks aren’t often at the top of growth investors’ lists, but insider activity tells a different story. At Kemper Corporation, five insiders bought a combined $580,000 worth of stock, a notable show of support. Kemper is an insurance holding company operating across two main segments:
With roots dating back to 1990, Kemper has a long track record in the U.S. insurance market. While the stock has been volatile, insiders seem to be betting on a turnaround. Insurance companies tend to benefit from higher interest rates, as they can earn more on their investment portfolios. At the same time, consumers continue to need protection for cars, homes, and families regardless of economic cycles, giving Kemper a level of defensive stability. For income-focused investors, the company also pays a modest dividend. With insiders stepping in, KMPR could be an undervalued way to play the insurance sector. |
Trade Algo
Is this your new #1 enemy in trading?
Imagine this scenario…You are a super-intelligent investor who can scan through millions of data, detect patterns, and execute savvy trades… in just minutes.
It would be an unfair advantage, right?
Welcome to the AI Age, where AI can make trading decisions in milliseconds.
Take Minotaur Capital as an example.
The hedge fund replaced human analysts with AI… and… ended up beating the benchmark index by more than two times.
Here's the good news...
You can get a taste of using A.I. technology to find the top momentum trades.
As a Behind the Markets reader, we’d like to offer you a SPECIAL gift where you can sign up for our SMS “dark pool alerts” for FREE.
Click here to claim FREE SMS dark pool alerts now.
Company: MaxCyte, Inc. (SYM: MXCT)
The third insider-buying standout is MaxCyte, Inc., a small-cap life sciences company focused on cell engineering and therapeutic development. At just over $1 per share, the stock is deep in small-cap territory, yet insiders clearly believe there’s upside — with five insiders purchasing nearly $500,000 worth of shares. MaxCyte develops and sells a platform of electroporation instruments under its ExPERT series, which allow for precise cell modification at various scales:
These tools are used by pharma and biotech companies in drug discovery, therapeutic development, and biomanufacturing. The company also generates recurring revenue through consumables and licensing agreements. Why might insiders be bullish? Biotech is notoriously volatile, but MaxCyte’s technology addresses a fast-growing field: cell and gene therapy. As pharmaceutical companies ramp up investment in advanced therapies, MaxCyte’s platforms could see greater adoption. With the stock beaten down, insiders may see the current price as a rare entry point ahead of potential catalysts. |
Found this helpful? Share it with others.
Written by Ian Cooper